Skip to content
Open access · CC-BY via OpenAlex

Activated mTOR signaling pathway in myofibers with inherited metabolic defect might be an evidence for mTOR inhibition therapies

Jing-Wei Lyu, Xuebi Xu, Kunqian Ji, Na Zhang, Yuan Sun, Dandan Zhao, Yuying Zhao, Chuanzhu Yan

Chinese Medical Journal · 2019 · ▲ 4 citations

Abstract

BACKGROUND: Abnormally activated mechanistic target of mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) (mTOR) pathway has been reported in several model animals with inherited metabolic myopathies (IMMs). However, the profiles of mTOR pathway in skeletal muscles from patients are still unknown. This study aimed to analyze the activity of mTOR pathway in IMMs muscles. METHODS: We collected muscle samples from 25 patients with mitochondrial myopathy (MM), lipid storage disease (LSD) or Pompe disease (PD). To evaluate the activity of mTOR pathway in muscle specimens, phosphorylation of S6 ribosomal protein (p-S6) and p70S6 kinase (p-p70S6K) were analyzed by Western blotting and immunohistochemistry. RESULTS: Western blotting results showed that p-p70S6K/p70S6K in muscles from LSD and MM was up-regulated when compared with normal controls (NC) (NC vs. LSD, U = 2.000, P = 0.024; NC vs. MM: U = 6.000, P = 0.043). Likewise, p-S6/S6 was also up-regulated in muscles from all three subgroups of IMMs (NC vs. LSD, U = 0.000, P = 0.006; NC vs. PD, U = 0.000, P = 0.006; NC vs. MM, U = 1.000, P = 0.007). Immunohistochemical study revealed that p-S6 was mainly expressed in fibers with metabolic defect. In MM muscles, most p-S6 positive fibers showed cytochrome C oxidase (COX) deficiency (U = 5.000, P = 0.001). In LSD and PD muscles, p-S6 was mainly overexpressed in fibers with intramuscular vacuoles containing lipid droplets (U = 0.000, P = 0.002) or basophilic materials (U = 0.000, P = 0.002). CONCLUSION: The mTOR pathway might be activated in myofibers with various metabolic defects, which might provide evidence for mTOR inhibition therapy in human IMMs.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1097/cm9.0000000000000144
Canonical
link ↗
Fetched
2026-11-12 MST

Cite this

APA
Lyu, J., Xu, X., Ji, K., Zhang, N., Sun, Y., Zhao, D., Zhao, Y., &amp; Yan, C. (2019). Activated mTOR signaling pathway in myofibers with inherited metabolic defect might be an evidence for mTOR inhibition therapies. <em>Chinese Medical Journal</em>. https://doi.org/10.1097/cm9.0000000000000144
Vancouver
Lyu J, Xu X, Ji K, Zhang N, Sun Y, Zhao D, et al. Activated mTOR signaling pathway in myofibers with inherited metabolic defect might be an evidence for mTOR inhibition therapies. Chinese Medical Journal. 2019. doi:10.1097/cm9.0000000000000144.
BibTeX
@article{jingwei2019Activa, title = {Activated mTOR signaling pathway in myofibers with inherited metabolic defect might be an evidence for mTOR inhibition therapies}, author = {Jing-Wei Lyu and Xuebi Xu and Kunqian Ji and Na Zhang and Yuan Sun and Dandan Zhao and Yuying Zhao and Chuanzhu Yan}, journal = {Chinese Medical Journal}, year = {2019}, doi = {10.1097/cm9.0000000000000144}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings